YENOM NOTICIAS

Qué está moviendo el mercado.

Noticias financieras organizadas para conectar titulares, símbolos, fuente, fecha y sentimiento con tu análisis y operativa.

BICX
Limpiar

Si escribes ticker, YENOM prioriza ese instrumento. Si lo dejas vacío puedes explorar el feed general o por tema.

globenewswire.comPOSITIVO

Life Sciences Virtual Investor Forum Agenda Announced for December 11th

NEW YORK, Dec. 09, 2025 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference series, announced the agenda for the Life Sciences Virtual Investor Forum to be held December 11th. Individual investors,…

globenewswire.comPOSITIVO

BioCorRx Reports Business Update for the Third Quarter of 2023

ANAHEIM, CA, Nov. 14, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – BioCorRx Inc. (OTCQB: BICX) (the “Company”), a developer and provider of innovative treatment programs for substance abuse and related disorders, today provided a business u…

globenewswire.comPOSITIVO

BioCorRx Submits Expanded Access Treatment Protocol to FDA for BICX104, Implantable Biodegradable Naltrexone Pellet for Treatment of Opioid Use Disorder

Company Hopes in 30 Days to Begin Making Its Drug Candidate Available to Help Patients and Address Public Health Crisis ANAHEIM, CA, Aug. 15, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire– BioCorRx Inc. (OTCQB: BICX) (the “Company”) today anno…

globenewswire.comPOSITIVO

BioCorRx Reports Business Update for the Second Quarter of 2023

On Track to Meet 2023 Regulatory Milestones ANAHEIM, CA, Aug. 14, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – BioCorRx Inc. (OTCQB: BICX) (the “Company”), a developer and provider of innovative treatment programs for substance abuse and re…

globenewswire.comPOSITIVO

BioCorRx Submits Fast Track Application to FDA for BICX104, an Implantable Biodegradable Naltrexone Pellet for The Treatment of Opioid Use Disorder

ANAHEIM, CA, July 18, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – BioCorRx Inc. (OTCQB: BICX) (the “Company”), a developer and provider of innovative treatment programs for substance abuse and related disorders, today announced the submiss…

globenewswire.comPOSITIVO

BioCorRx Provides Business Update for the First Quarter of 2023

Revenue Increases 97% ANAHEIM, CA, May 16, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – BioCorRx Inc. (OTCQB: BICX) (the “Company”), a developer and provider of innovative treatment programs for substance abuse and related disorders, today…

globenewswire.comPOSITIVO

BioCorRx Provides Business Update for 2022

Revenue Increases 343% for 2022 Due to Increased Number of Patients Treated at Licensed Clinics ANAHEIM, CA, April 03, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire -- BioCorRx Inc. (OTCQB: BICX) (the “Company”), a developer and provider of in…

globenewswire.comPOSITIVO

BioCorRx Announced Interim Positive Safety and Pharmacokinetic Results of Phase 1 Clinical Trial at 4th Annual NIH HEAL Initiative Investigator Meeting

BICX104 was Well Tolerated with No Serious Adverse Events Reported and Achieved 84 Days of Therapeutic Naltrexone Plasma ConcentrationsBICX104 Subjects Experienced Better 84-Day Treatment Adherence Than Vivitrol® SubjectsCompany Seeking FD…

globenewswire.comPOSITIVO

BioCorRx Attended 4th Annual NIH HEAL Initiative Investigator Meeting; Shares Update on BICX104 Data

ANAHEIM, CA, Feb. 23, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – BioCorRx Inc. (OTCQB: BICX) (the “Company”), a developer and provider of innovative treatment programs for substance use and related disorders, announced today that Dr. Andr…

globenewswire.comPOSITIVO

BioCorRx to Present at Sequire Biotechnology Conference on February 2nd

Presentation on Thursday, February 2, 2023 at 2:00 PM ET ANAHEIM, CA, Jan. 27, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire -- BioCorRx Inc. (OTCQB: BICX) (the “Company”), a developer and provider of innovative treatment programs for substanc…

globenewswire.comPOSITIVO

BioCorRx Appoints Pharmaceutical & Finance Veteran Harsha Murthy to the Board of Directors

ANAHEIM, CA, Jan. 24, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire -- BioCorRx Inc. (OTCQB: BICX) (the “Company”), a developer and provider of innovative treatment programs for substance use and related disorders, today announced that Mr. Har…

globenewswire.comPOSITIVO

BioCorRx Announces Completion of Treatment Phase of Study Subjects and Preliminary Safety Data from Phase I Clinical Trial of BICX104, an Implantable Naltrexone Pellet for the Treatment of Opioid Use Disorder

ANAHEIM, CA, Jan. 19, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – BioCorRx Inc. (OTCQB: BICX) (the “Company”), a developer and provider of innovative treatment programs for substance use and related disorders, today announced an update fro…

globenewswire.comPOSITIVO

BioCorRx Partners with Government Plus to Expand its Beat Addiction Recovery Program in the United States

ANAHEIM, CA, Dec. 07, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- BioCorRx Inc. (OTCQB: BICX) (the “Company”), a developer and provider of innovative treatment programs for substance abuse and related disorders, today announced that it ha…

globenewswire.comPOSITIVO

BioCorRx Board of Directors Approves Exploration of Potential Spin-Off of BioCorRx Pharmaceuticals, Inc.

ANAHEIM, CA, Nov. 22, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- BioCorRx Inc. (OTCQB: BICX) (the “Company”), a developer and provider of innovative treatment programs for substance abuse and related disorders, today announced that its b…

globenewswire.comPOSITIVO

BioCorRx Provides Business Update for the Third Quarter of 2022

ANAHEIM, CA, Nov. 15, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire --BioCorRx Inc. (OTCQB: BICX) (the “Company”), a developer and provider of innovative treatment programs for substance abuse and related disorders, today provided a business u…

globenewswire.comPOSITIVO

BioCorRx Completes Final Subject Enrollment in Phase I Clinical Trial of BICX104, an Implantable Naltrexone Pellet for the Treatment of Opioid Use Disorder

ANAHEIM, CA, Oct. 13, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – BioCorRx Inc. (OTCQB: BICX) (the “Company”), a developer and provider of innovative treatment programs for substance abuse and related disorders, today announced that the la…

globenewswire.comPOSITIVO

BioCorRx to Present at the H.C. Wainwright 24th Annual Global Investment Conference

ANAHEIM, CA, Sept. 06, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – BioCorRx Inc. (OTCQB: BICX) (the “Company”), a developer and provider of innovative treatment programs for substance abuse and related disorders, today announced that Lourd…

globenewswire.comPOSITIVO

BioCorRx Provides Business Update for the Second Quarter of 2022

ANAHEIM, CA, Aug. 16, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – BioCorRx Inc. (OTCQB: BICX) (the “Company”), a developer and provider of innovative treatment programs for substance abuse and related disorders, today provided a business u…

globenewswire.comPOSITIVO

BioCorRx to Participate in the Benzinga All Access Event on July 15th

ANAHEIM, CA, July 13, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – BioCorRx Inc. (OTCQB: BICX) (the “Company”), a developer and provider of innovative treatment programs for substance abuse and related disorders, today announced that Brady…

globenewswire.comPOSITIVO

BioCorRx Announces First Subject Dosed in Phase I Clinical Trial of BICX104, an Implantable Naltrexone Pellet for the Treatment of Opioid Use Disorder

ANAHEIM, CA, June 30, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- BioCorRx Inc. (OTCQB: BICX) (the “Company”), a developer and provider of innovative treatment programs for substance abuse and related disorders, today announced that the f…

globenewswire.comPOSITIVO

BioCorRx Featured on LiveNOW from FOX

ANAHEIM, CA, June 17, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – BioCorRx Inc. (OTCQB: BICX) (the “Company”), a developer and provider of innovative treatment programs for substance abuse and related disorders, today announced that Tom We…

globenewswire.comPOSITIVO

BioCorRx to Present at the LD Micro Invitational XII on June 7th

ANAHEIM, CA, May 31, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- BioCorRx Inc. (OTCQB: BICX) (the “Company”), a developer and provider of innovative treatment programs for substance abuse and related disorders, today announced that Lourde…

globenewswire.comPOSITIVO

BioCorRx and 2B3D to Pilot First-of-its-Kind PTSD and Addiction Treatment Solutions for Veterans in Metaverse Setting

Collaboration to create a synergistic treatment offering, combining BioCorRx’s MAT treatment program and 2B3D virtual reality technology Plans toward expanding the offering to other at-risk groups upon evaluating results of pilot with vete…

globenewswire.comPOSITIVO

BioCorRx Business Update for the First Quarter of 2022

ANAHEIM, CA, May 17, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – BioCorRx Inc. (OTCQB: BICX) (the “Company”), a developer and provider of innovative treatment programs for substance abuse and related disorders, today provided a business up…

finance.yahoo.comPOSITIVO

Keynotes, Educational Panels and 88 Companies to Present at the Planet MicroCap Showcase on May 3-5, 2022 at Bally's Hotel & Casino in Las Vegas, NV

LOS ANGELES, CA / ACCESSWIRE / April 27, 2022 / SNN Network presents the Planet MicroCap Showcase taking place on May 3-5, 2022, where 88 MicroCap public and private companies will be presenting at Bally's Hotel & Casino in Las Vegas, NV.…

globenewswire.comPOSITIVO

BioCorRx Begins Recruitment for Clinical Trial of BICX104, an Implantable Naltrexone Pellet for the Treatment of Opioid Use Disorder

ANAHEIM, CA, April 27, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- BioCorRx Inc. (OTCQB: BICX) (the “Company”), a developer and provider of innovative treatment programs for substance abuse and related disorders, today announced that it h…

globenewswire.comPOSITIVO

BioCorRx Announces Additional Award of Nearly $100,000 from NIDA for BICX104, its Implantable Naltrexone Pellet for the Treatment of Opioid Use Disorder

ANAHEIM, CA, April 11, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- BioCorRx Inc. (OTCQB: BICX) (the “Company”), a developer and provider of innovative treatment programs for substance abuse and related disorders, today announced that it h…

globenewswire.comPOSITIVO

BioCorRx Provides 2021 Year-End Business Update

ANAHEIM, CA, April 01, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- BioCorRx Inc. (OTCQB: BICX) (the “Company”), a developer and provider of innovative treatment programs for substance abuse and related disorders, today provided a year-end…

globenewswire.comPOSITIVO

BioCorRx to Participate in Two Upcoming Conferences

ANAHEIM, CA, March 22, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- BioCorRx Inc. (OTCQB: BICX) (the “Company”), a developer and provider of innovative treatment programs for substance abuse and related disorders, today announced that mana…

globenewswire.comPOSITIVO

BioCorRx Announces IRB Approval to Begin Phase I Clinical Trial of BICX104, an Implantable Biodegradable Naltrexone Pellet for the Treatment of Opioid Use Disorder

ANAHEIM, CA, March 16, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- BioCorRx Inc. (OTCQB: BICX) (the “Company”), a developer and provider of innovative treatment programs for substance abuse and related disorders, today announced it has re…

globenewswire.comPOSITIVO

BioCorRx Announces Orange County Research Center as Clinical Trial Site for First-In-Human Clinical Trial of BICX104

ANAHEIM, CA, Feb. 14, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – BioCorRx Inc. (OTCQB: BICX) (the “Company”), a developer and provider of innovative treatment programs for substance abuse and related disorders, is pleased to announce that…

globenewswire.comPOSITIVO

BioCorRx to Present at the H.C. Wainwright BioConnect 2022 Conference

ANAHEIM, CA, Jan. 05, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- BioCorRx Inc. (OTCQB: BICX) (the “Company”), a developer and provider of innovative treatment programs for substance abuse and related disorders, today announced that Lourd…

globenewswire.comPOSITIVO

BioCorRx Appoints Drug Delivery Expert Jie Shen, Ph.D., to Scientific Advisory Board

ANAHEIM, CA, Dec. 09, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- BioCorRx Inc. (OTCQB: BICX) (the “Company”), a developer and provider of innovative treatment programs for substance abuse and related disorders, today announced the appoin…

globenewswire.comPOSITIVO

BioCorRx to Participate in the Benzinga All Access Event on December 2nd

ANAHEIM, CA, Nov. 24, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- BioCorRx Inc. (OTCQB: BICX) (the “Company”), a developer and provider of innovative treatment programs for substance abuse and related disorders, today announced that Lourd…

globenewswire.comPOSITIVO

BioCorRx Acquires Intellectual Property for Drug Delivery

Patent Application Covers Solid Implant Formulation for Drug Delivery ANAHEIM, CA, Nov. 22, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire – BioCorRx Inc. (OTCQB: BICX) (the “Company”), a developer and provider of innovative treatment programs…

globenewswire.comPOSITIVO

BioCorRx Provides Business Update for the Third Quarter of 2021

ANAHEIM, CA, Nov. 16, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- BioCorRx Inc. (OTCQB: BICX) (the “Company”), a developer and provider of innovative treatment programs for substance abuse and related disorders, today provided a business…